Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 24 of 1217 for:    adenosine

CT Perfusion Changes in GI Cancer During Adenosine Vasodilation Test

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02074124
Recruitment Status : Completed
First Posted : February 28, 2014
Last Update Posted : February 28, 2014
Information provided by (Responsible Party):
Martin Lundsgaard Hansen, Rigshospitalet, Denmark

Brief Summary:
The aim of this study was to investigate changes in abdominal tissue perfusion during adenosine vasodilation. Our hypotheses were that CT perfusion measurements are altered by changes in the circulatory system mediated by adenosine, and a more differentiated assessment of the circulatory capacity of abdominal tumours could be achieved by sequential rest and adenosine vasodilation CT perfusion measurements.

Condition or disease
Esophageal Cancer Gastric Cancer

Layout table for study information
Study Type : Observational
Actual Enrollment : 15 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Abdominal Tissue Perfusion Changes in Esophageal and Gastric Cancer During Adenosine Vasodilation Measured With Computed Tomography (CT) Perfusion
Study Start Date : October 2012
Actual Primary Completion Date : August 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stomach Cancer
Drug Information available for: Adenosine

Adenosine Vasodilation test
Group scanned with CT perfusion during adenosine vasodilation test.
Reference group
Group scanned twice without adenosine vasodilation test for a reference. No randomization.

Primary Outcome Measures :
  1. Change in arterial flow during adenosine vasodilation test (CT perfusion parameter) [ Time Frame: 0 min and 15 min ]

Secondary Outcome Measures :
  1. Change in Blood pressure during adenosine vasodilation test [ Time Frame: 0 min and 15 min ]
  2. Change in Heart rate during adenosine vasodilation test [ Time Frame: 0 min and 15 min ]
  3. Change in Area under arterial input curve during adenosine vasodilation test [ Time Frame: 0 min and 15 min ]
    Area Under Curve (AUC) is correlated to cardiac output

  4. Change in Blood volume (CT perfusion parameter) during adenosine vasodilation test [ Time Frame: 0 min and 15 min ]
  5. Change in Permeability (CT perfusion parameter) during adenosine vasodilation test. [ Time Frame: 0 min and 15 min ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with biopsy proven tumors in esophagus or stomach

Inclusion Criteria:

  • Tumour larger than 1.5 cm on diagnostic CT
  • Normal serum creatinine
  • Age above 18
  • Informed written and oral consent.

Exclusion Criteria:

  • Contrast allergy or contrast induced nephropathy
  • BMI > 40
  • Asthma or Chronic Obstructive Lung Disease
  • Heart failure (NYHA III+)
  • Heart conduction disorder
  • Atrial fibrillation
  • 2nd/3rd Heart block
  • Long QT syndrome
  • Wolf Parkinson White Syndrome
  • Moderate / severe aortic stenosis
  • Haemodynamic contraindications for adenosine, systolic pressure below 90

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02074124

Layout table for location information
Copenhagen, Denmark, 2100
Sponsors and Collaborators
University of Copenhagen
Layout table for investigator information
Principal Investigator: Martin L Hansen, MD Rigshospitalet, Denmark

Layout table for additonal information
Responsible Party: Martin Lundsgaard Hansen, MD, Rigshospitalet, Denmark Identifier: NCT02074124    
Other Study ID Numbers: H-3-2012-067
H-3-2012-067 ( Other Identifier: Committees on Biomedical Research for the Capital Region of Denmark )
First Posted: February 28, 2014    Key Record Dates
Last Update Posted: February 28, 2014
Last Verified: February 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action